中山醫學大學機構典藏 CSMUIR:Item 310902500/24883
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17938/22957 (78%)
造访人次 : 7391124      在线人数 : 183
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24883


    题名: High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy
    作者: Chang, WY;Chiu, YC;Chiu, FW;Hsu, YC;Tseng, TC;Cheng, PN;Yang, SS;Liu, CJ;Su, TH;Yang, HC;Liu, CH;Chen, PJ;Chen, DS;Kao, JH
    关键词: Chronic hepatitis B;prophylaxis;entecavir;tenofovir;hematological cancer;hepatic failure;liver decompensation
    日期: 2020
    上传时间: 2022-08-09T08:09:33Z (UTC)
    出版者: OXFORD UNIV PRESS INC
    ISSN: 0022-1899
    摘要: Background: Prophylaxis with nucleos(t)ide analogue (NA) is recommended to prevent hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients receiving rituximab-based B-cell depletion therapy. However, little is known about the risk of clinical relapse after withdrawal of NA. Methods: We retrospectively analyzed 77 noncirrhotic HBsAg carriers with hematological cancer who received rituximab-containing chemotherapy. All of them received either prophylactic entecavir or tenofovir therapy. The risk of clinical relapse and hepatic decompensation after cessation of NA was explored. Results: Clinical relapse and hepatic decompensation developed in 25 (32.5 %) and 11 (14.3 %) of the patients, respectively, and 2 patients died of hepatic decompensation. Most of the hepatic events occurred within 1 year (20 of 25; 80.0%) after stopping NA. A higher pretreatment viral load (>= 2000 vs <2000 IU/mL) was associated with increased risks of clinical relapse (hazard ratio, 3.47; 95% confidence interval, 1.56-7.73) and hepatic decompensation (9.91; 2.14-45.92). Of 51 patients with pretreatment viral load <2000 IU/mL, clinical relapse occurred in 10 (19.6 %) and hepatic decompensation in 2 (3.9%). Conclusions: Pretreatment HBV DNA >= 2000 IU/mL is associated with increased risk of liver-related disease after cessation of prophylactic NA therapy in patients who received rituximab-containing chemotherapy.
    URI: http://dx.doi.org/10.1093/infdis/jiaa256
    https://www.webofscience.com/wos/woscc/full-record/WOS:000577175900016
    https://ir.csmu.edu.tw:8080/handle/310902500/24883
    關聯: JOURNAL OF INFECTIOUS DISEASES ,2020 ,v222 ,issue 8 ,p1345-1352
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML155检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈